The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon α-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1

Journal of Viral Hepatitis

Volumn 13, Issue 8, 2006, Pages 552-559

  Brandao C ^a   Barone, A ^b   Carrilho, F ^b   Silva, A ^c   Patelli, M ^d   Caramori, C ^e   Focaccia, R ^f   Pereira, L ^g   Pedroso, M ^h   Tatsch, F ⁱ   Pessoa, M ^f  

^a HOSPITAL UNIVERSITÁRIO GAFFRÉE E GUINLE   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^e SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^f Emilio Ribas Infectious Diseases Institute   (Brazil)

^g FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^h FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

ⁱ Roche Brazil   (Brazil)

Author keywords

Hepatitis C; Peginterferon 2a; Ribavirin; Treatment duration

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; INSOMNIA; IRRITABILITY; LEUKOPENIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RIGOR; SIDE EFFECT; SKIN MANIFESTATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 33746239298     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2006.00758.x     Document Type: Article

References (17)

1. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000; 32(Suppl. 1): 98-112.
2. World Health Organization - Fact sheet #164. http:// www.who.int/ mediacentre/factsheets/fs164/en/ (revised July, 14th, 2005).
3. Focaccia R, Conceição O, Sette H et al. Estimated prevalence of viral hepatitis in the general population of the municipality of São Paulo, measures by serologic survey of a stratified, randomized and residence-based population. Braz J Infect Dis 1998; 2: 269-284.
4. Weekly Epidemiological Record #49. World Health Organ 1999; 74: 421-428 Available at: http://www.who.int/ docstore/wer/pdf/1999/wer7449.pdf (last accessed 16 May 2006).
5. Herrine S. Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med 2002; 136(10): 747-757.
6. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med 2001; 345(1): 41-52.
7. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C: 2002 -June 10-12, 2002. Hepatology 2002; 36(5 Suppl. 1): S3-S20.
8. Adis R&D profiles: PEG-interferon-α-2a (40KD): PEG IFN-α-2a (40KD), PEGASYS®, RO253036. Drugs R&D 1999; 2: 278-280.
9. Harris J, Martin N, Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001; 40(7): 539-551.
10. Reddy R. Controlled - release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 2000; 34: 915-923.
11. McHutchinson J, Gordon S, Schiff E et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21): 1485-1492.
12. Davis G, Esteban-Mur R, Rustgi V et al. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21): 1493-1499.
13. Poynard T, Marcellin P, Lee S et al. Randomized trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352: 1426-1432.
14. Hadziyannis S, Sette H, Morgan T et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-355.
15. Fried M, Shiffman M, Reddy R et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
16. Ferenci P, Fried M, Shiffman M, Reddy R, Scheafer S, Chaneac M. A dynamic model to predict sustained virological response to combination therapy with peginterferon alfa-2a (40KD) (PEGASYS®) and ribavirin (COPEGUS®) in patients with chronic hepatitis C infected with HCV genotype 1. Hepatology 2003; 38(4 Supp. 1): 635A.
17. Foster G. Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004; 20: 825-830.